OVARIAN CANCER

This study tests whether adding heated chemotherapy directly into the abdomen during surgery helps people with stage III ovarian cancer live longer. About 538 participants will be randomly assigned to standard surgery alone or surgery plus the heated chemo. The main goal is to se…

This study tested a combination of three drugs—nivolumab, bevacizumab, and rucaparib—in 72 people whose ovarian, fallopian tube, or peritoneal cancer had returned after standard treatment. The goal was to see if the drugs could shrink tumors and control the disease. Participants …

This study offers continued treatment with avelumab for people with advanced cancers like lung, ovarian, or bladder cancer who are already benefiting from it in earlier Pfizer studies. The goal is to keep providing the drug and monitor safety and survival. About 68 participants w…

This study tests a drug called IMP4297 (a PARP inhibitor) as a maintenance treatment after first-line chemotherapy for people with advanced ovarian cancer. The goal is to see if it can delay cancer progression. About 404 participants are randomly assigned to receive either IMP429…

This study tests a combination of two drugs, ONC-392 and pembrolizumab, in 58 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the combo can shrink tumors and control the disease. Participants must have a specific type of…

This study looks at whether adding Juice Plus+ and Juice Plus+ Complete supplements to the diet can improve health outcomes for ovarian cancer patients who are in remission. About 75 participants will either receive the supplements or just dietary counseling. Researchers will mea…

This study tests two drugs, avutometinib and defactinib, in 16 Japanese patients whose low-grade serous ovarian cancer has returned after platinum-based chemotherapy. The goal is to see if the combination can shrink or control the cancer. Participants must have measurable disease…

This study aimed to test the safety and effectiveness of combining two drugs, bemarituzumab and bevacizumab, in people with advanced or metastatic endometrial, ovarian, or cervical cancers that have a specific protein (FGFR2b). The trial was withdrawn before enrolling any partici…

This early-phase study tests an experimental drug called MOMA-313, given alone or with another drug (olaparib), in people with advanced solid tumors that have a specific DNA repair problem (HR deficiency). The main goals are to check safety, find the best dose, and see if the dru…

This study tests whether a combination of three drugs (olaparib, durvalumab, and UV1) can help keep ovarian cancer from coming back in people who have already had treatment. It involves 188 adults with a type of ovarian cancer that does not have a BRCA gene mutation. The goal is …

This study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, called T cells, which are genetically modified in a lab to better recognize and attack cancer cells. The main goa…

This early-stage study tests an experimental pill, ATV-1601, in people with advanced solid tumors (including certain breast, ovarian, and prostate cancers) that have a specific AKT1 gene mutation. The main goals are to check the drug's safety, find the best dose, and see how the …

This early-phase study tests a new drug called AB598, alone or with other treatments, in about 40 people with advanced solid tumors like lung, bladder, or ovarian cancer. The main goal is to check if the drug is safe and tolerable. Participants must have measurable tumors and be …

This study tests whether combining two drugs—atezolizumab (an immunotherapy) and tivozanib (a targeted therapy)—can shrink tumors in cancers that typically don't respond to immunotherapy alone. About 29 adults with advanced bile duct, gallbladder, breast, neuroendocrine, ovarian,…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel, with or without bevacizumab) can slow the growth of ovarian cancer that has stopped responding to platinum-based treatments. About 643 adults with this type of ovarian cance…

This study looks at whether removing the fallopian tubes at the same time as a hysterectomy (for non-cancer reasons) can lower the chance of getting ovarian cancer later. About 4,400 women under 55 are taking part. Researchers are checking if the extra step is safe, doesn't harm …

This study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian, fallopian tube, or peritoneal cancer. About 88 newly diagnosed patients will receive either the drug combo or chemo alone before and after surgery. Th…

This study tests an experimental drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking signals that help it grow. About 534 adults with various cancers, including…

This study tests a new drug called PF-07104091, alone or with other medicines, in people with advanced breast, lung, or ovarian cancer that has spread or come back. The goal is to find a safe dose and see if it shrinks tumors. About 157 adults will take part, and the drug is give…

This early-phase study tests a personalized cell therapy called T-Plex for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize and attack cancer cells. The main goal is to check s…

This study tests whether the drug olaparib can help keep advanced ovarian cancer from coming back after initial chemotherapy. It includes 366 women with a specific type of ovarian cancer (high-grade serous or endometrioid) that does not have a BRCA gene mutation. Participants rec…

This phase 2 study tests a personalized cell therapy (ADP-A2M4CD8) alone or with the drug nivolumab in people with a specific type of recurrent ovarian cancer. Participants must have certain genetic markers (HLA-A*02 and MAGE-A4). The goal is to see if the treatment can shrink tu…

This early-stage study tests two experimental drugs (botensilimab and balstilimab) that help the immune system fight cancer. It includes about 500 adults with advanced solid tumors like lung, ovarian, or colorectal cancer that haven't responded to standard treatments. The main go…

This early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…

This early-phase trial tests a new treatment called FT536 for people with ovarian, fallopian tube, or primary peritoneal cancer that has come back. The treatment is given directly into the belly three times in one week, after a short course of chemotherapy to prepare the body. On…

This study tests a new treatment for ovarian cancer using specially engineered immune cells (OC-EIEs) designed to target cancer. About 20 women with advanced ovarian cancer will receive the cells to see if it is safe and shrinks tumors. The goal is to control the disease, not cur…

This study offers continued access to the drug olaparib for people with ovarian or breast cancer who were already benefiting from it in a previous clinical trial. About 185 participants will keep receiving treatment as long as their doctor believes it helps them. The main goal is…

This study tested whether adding the drug olaparib to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced ovarian cancer live longer without their disease getting worse. It included 162 patients whose cancer had previously responded to platinum-based tre…

This early-phase study tests an experimental cell therapy called P-MUC1C-ALLO1 in 180 adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a pro…

This study tests a new drug called CYH33 in 93 women whose ovarian, fallopian tube, or peritoneal clear cell cancer has returned or not gone away. The drug targets a specific genetic change (PIK3CA mutation) to try to shrink tumors. Participants must have already tried standard c…

This study looks at whether having surgery right away or after chemotherapy works better for people with advanced ovarian cancer. About 800 women took part. The goal is to see which approach helps them live longer.

This study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma). The therapy takes a patient's own immune cells and genetically equips them to recognize and attack tumors that …

This study tests whether the immunotherapy drug nivolumab, alone or combined with ipilimumab, can shrink tumors in people with advanced clear cell carcinoma of the ovary, fallopian tube, peritoneum, or other organs. About 46 participants with recurrent or metastatic disease will …

This phase 3 trial tests whether adding heated chemotherapy directly into the abdomen during surgery helps people with stage III ovarian cancer live longer without the disease coming back. About 362 participants will receive either standard surgery alone or surgery plus the heate…

This study tests a personalized immunotherapy called Vigil in 92 women with advanced ovarian cancer who are currently cancer-free after surgery and chemotherapy. The treatment uses the patient's own tumor cells to train the immune system to fight any remaining cancer cells. The m…

This early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to target and attack cancer cells while sparing healthy ones. The study will check if the drug is safe and what dose wor…

This early-phase trial tests a treatment for adults with metastatic solid tumors (like colorectal, lung, or breast cancer) that have a specific genetic change called KRAS. Doctors take a person's own white blood cells, modify them in a lab to better recognize and attack cancer ce…

This study is testing an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors like ovarian, breast, pancreatic, and prostate cancer. The goal is to see if the drug is safe and tolerable when given alone or with other cancer treatments. About 70…

This study tests a drug called BGB-290 (Pamiparib) as a maintenance treatment for people with recurrent ovarian cancer who have already responded to platinum-based chemotherapy. The goal is to see if taking this pill regularly can delay the cancer from coming back. About 224 part…

This study tests several targeted therapies in people with rare ovarian cancers that have come back or not responded to treatment. Researchers match each patient to a drug based on specific markers found in their tumor. The goal is to see if these personalized treatments can shri…

This phase 2 study tested whether combining an experimental vaccine (DPX-Survivac) with an immunotherapy drug (pembrolizumab) and low-dose chemotherapy can shrink tumors in people with advanced ovarian, fallopian tube, or peritoneal cancer. The vaccine trains the immune system to…

This early-stage study tests two drugs, niraparib and neratinib, together in people with advanced solid tumors or ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find the safest dose and see if the combination can stop the cancer from growing for a…

This study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian cancer live longer without their cancer growing. About 615 newly diagnosed patients who had surgery to remove most of their cancer will receive either …

This early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…

This study tests whether the drug bevacizumab (Avastin) can help control ovarian, fallopian tube, or primary peritoneal cancer that was still found during a second-look surgery. About 35 adults with advanced-stage cancer who already had standard chemotherapy and surgery will rece…

This study tests a new combination of drugs for people with ovarian cancer that has come back and no longer responds to platinum-based chemotherapy. The treatment adds ALX148 (which targets a protein called CD47 on cancer cells) to standard chemotherapy (liposomal doxorubicin) an…

This study tests two new drug combinations for people with a type of ovarian cancer that has stopped responding to a standard treatment called PARP inhibitors. The trial involves 63 participants and aims to see if the new combinations can shrink or control the tumor. The goal is …

This early-phase study tests a personalized cell therapy (ADP-A2M4CD8) for people with advanced cancers like lung, ovarian, or melanoma that have a specific marker called MAGE-A4. The treatment uses the patient's own immune cells, modified to better attack the cancer, and is give…

This study looks at whether a simple saliva test can help doctors tell if an ovarian mass is cancerous, borderline, or benign. Researchers are collecting saliva from 746 women before and after surgery to see if certain RNA molecules can accurately diagnose ovarian cancer. The goa…

This study is testing whether a special MRI contrast agent, called hyperpolarized 13-C pyruvate, can help doctors see how aggressive ovarian cancer is. About 30 people at high risk for ovarian cancer will take part. The main goal is to check safety and see if the imaging works on…

This study looks at how to quickly identify depression in women with ovarian, peritoneal, or fallopian tube cancer. It compares a special support program with enhanced standard care to see which better improves quality of life. About 409 women on active cancer treatment are takin…

This study tests whether a web-based group program can improve quality of life and reduce stress for ovarian cancer survivors. About 326 survivors will take part, comparing a mindfulness program to a healthy lifestyle program. The goal is to help women feel better emotionally and…

This study compares two ways of giving high-dose radiation to people whose cancer has spread to bones, spine, soft tissue, or lymph nodes. One group gets a single large dose in one day, the other gets a slightly higher total dose spread over three days. The goal is to see which s…

This pilot study tested whether a prehabilitation program is practical and helpful for women with advanced ovarian cancer who receive chemotherapy before surgery. The program aims to improve patients' strength and well-being before their operation. 22 women participated, and the …

This study tests a program called Journey Ahead that helps women with gynecologic cancers (like ovarian, endometrial, or cervical cancer) improve their coping and communication skills. About 30 women who have been diagnosed or had a recurrence in the past 5 years will take part. …

This study looks at four different tools to help people who have had cancer improve their diet and physical activity. About 353 cancer survivors will try these tools to see which ones work best. The goal is to find simple ways to help survivors follow healthy lifestyle guidelines…

This study aims to create a repository of biological samples—such as tumors, blood, and urine—from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. Researchers will use these samples in future studies to understand DNA changes that drive cancer. P…

This study aims to find genetic and protein changes in ovarian, endometrial, and cervical cancers. Researchers will analyze tissue samples from 300 participants to see how these changes relate to patient outcomes. The goal is to improve understanding of these cancers, not to test…

This study looks at whether combining PET/MRI scans with blood and tissue tests can create a detailed profile of high-grade serous ovarian cancer. Researchers hope this will help predict how tumors respond to treatment and allow for more personalized care. The study involves 10 p…

This study tests whether a reminder sent to doctors can increase the number of patients with suspicious ovarian masses who are referred to a gynecologic oncology specialist within 30 days. About 20 women with concerning imaging results will be included, and their referral rates w…

This study looks at whether a blood test that detects tiny bits of tumor DNA (ctDNA) can help doctors decide who needs extra treatment after ovarian cancer surgery. Researchers will analyze stored blood samples from 50 patients taken before and after surgery. The goal is to see i…

This study looks at the diet, exercise habits, emotions, and social support of women who have lived with ovarian cancer for at least seven years. Researchers want to understand what factors may help these long-term survivors. The study does not provide any treatment—it only colle…

This study interviews 24 women aged 25 or older who have a BRCA1 or BRCA2 mutation to learn how they might use polygenic risk scores and multi-cancer early detection tests when deciding about cancer screening or risk-reducing surgery. The goal is to better understand women's atti…

This study looks at whether thin slices of ovarian tumors grown in a lab can predict how well a patient will respond to chemotherapy. Researchers will test drugs on these slices and compare the results to the patient's actual treatment outcome. If successful, this approach could …

This study looks at how much time people with advanced breast or ovarian cancer spend on cancer-related tasks like appointments, travel, medications, and paperwork. About 78 participants will use a smartphone app for 28 days to track their activities and complete daily surveys. T…

This study follows about 400 adults who previously received A2Bio gene therapy for various solid tumors, including lung, colon, and pancreatic cancers. The main goal is to track long-term safety and see how well the treatment effects last over time. Participants do not receive ne…

This study looks at people with advanced ovarian cancer who have a second look laparoscopy after finishing their first round of chemotherapy. The goal is to see if small amounts of cancer left behind affect long-term health, and to check if the procedure is safe and practical. Ab…

This study collects DNA from over 21,000 New York cancer patients to look for inherited gene changes linked to several cancer types. It is an exploratory project that does not offer treatment but aims to find clues for future research. Participants include people with breast, col…

This study follows 100 women with breast or gynecological cancer to see if what they eat in the month before starting chemotherapy is linked to levels of a protein called hepcidin. Researchers will also check if hepcidin levels relate to how much of the planned chemo dose patient…

This study looks at a new approach to genetic testing for people with ovarian, prostate, or pancreas cancer. Instead of always sending patients to a genetic counselor, doctors offer the test and counselors share results by phone. The goal is to see how this affects patient distre…

This study looks at how diet, lifestyle, and genetics influence the risk of getting endometrial cancer. Researchers will compare women who have or had the cancer with those who do not. The goal is to identify factors that may lead to the disease. About 1,315 women from New Jersey…

This study is testing a new genetic test (called Gersom panel) in 4,000 people with breast, ovarian, or colorectal cancer. The goal is to see if the test can accurately find inherited genetic risks and tumor mutations that might guide treatment choices. Participants provide blood…

This study tests whether a blood test (liquid biopsy) can be used instead of multiple tissue samples to see how ovarian cancer changes over time. Twenty newly diagnosed patients will give blood and tissue samples during their treatment for up to 2 years. The goal is to see if the…